Results 201 to 210 of about 291,532 (299)

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Biomechanical and histomorphometric characterization of the melatonin treatment effect in the carotid artery subjected to hypobaric hypoxia. [PDF]

open access: yesFront Bioeng Biotechnol
Rivera E   +7 more
europepmc   +1 more source

Discovering new hub genes of dilated cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Dilated cardiomyopathy (DCM) has a poor prognosis and exhibits a complex and diverse aetiology and genetic profile. The genes responsible for the pathogenesis of DCM have not been fully identified. The present study aimed to explore new hub genes of DCM by mining the human DCM databases and further by experimental validation.
Jun‐Yan Zhu   +9 more
wiley   +1 more source

Identification of serum C4BPA as a potential diagnostic marker of right ventricular remodelling via proteomic analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Right ventricular (RV) remodelling, a progressive condition characterized by maladaptive cardiac structural and functional changes, primarily results from prolonged pressure overload in patients with pulmonary hypertension (PH). Accurate, universal and easy‐to‐use biomarkers for assessing the severity of RV remodelling are lacking.
Xuenan Wang   +5 more
wiley   +1 more source

Length of stay and prior heart failure admission in frailty and heart failure: A systematic review and meta‐analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The aim of this study was to compare the differences in length of stay (LoS) and prior hospitalization due to heart failure (HHF) in patients with HF and frailty versus without frailty. Methods and results From inception until August 2024, PubMed, Scopus, Web of Science and Cochrane Library were searched.
Konstantinos Prokopidis   +5 more
wiley   +1 more source

Microvascular endothelial dysfunction in vascular senescence and disease. [PDF]

open access: yesFront Cardiovasc Med
Kasal DA   +4 more
europepmc   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy